Bharath Chelluboina1, Koteswara Rao Nalamolu1, Gustavo G Mendez1, Jeffrey D Klopfenstein1,2,3, David M Pinson4, David Z Wang5,3, Krishna Kumar Veeravalli1,2,5. 1. Departments of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA. 2. Departments of Neurosurgery, University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA. 3. Comprehensive Stroke Center, Illinois Neurological Institute, OSF HealthCare System, Saint Francis Medical Center, Peoria, Illinois, USA. 4. Departments of Pathology, University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA. 5. Departments of Neurology, University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA.
Abstract
BACKGROUND/AIMS: Stem cell treatment is one of the potential treatment options for ischemic stroke. We recently demonstrated a protective effect of human umbilical cord blood-derived mesenchymal stem cells (HUCB-MSCs) in a rat model of ischemic stroke. The treatment attenuated apoptosis and prevented DNA damage. A collection of published studies, including several from our laboratory, indicated the induction and detrimental role for several matrix metalloproteinases (MMPs) in post-stroke brain injury. We hypothesized that the HUCB-MSCs treatment after focal cerebral ischemia prevents the dysregulation of MMPs and induces the expression of endogenous tissue inhibitors of metalloproteinases (TIMPs) to neutralize the elevated activity of MMPs. METHODS: To test our hypothesis, we administered HUCB-MSCs (0.25 million cells/animal and 1 million cells/animal) intravenously via tail vein to male Sprague-Dawley rats that were subjected to a transient (two-hour) right middle cerebral artery occlusion (MCAO) and one-day reperfusion. Ischemic brain tissues obtained from various groups of rats seven days after reperfusion were subjected to real-time PCR, immunoblot, and immunofluorescence analysis. RESULTS: HUCB-MSCs treatment prevented the induction of MMPs, which were upregulated in ischemia-induced rats that received no treatment. HUCB-MSCs treatment also prevented the induction of TIMPs expression. The extent of prevention of MMPs and TIMPs induction by HUCB-MSCs treatment is similar at both the doses tested. CONCLUSION: Prevention of stroke-induced MMPs upregulation after HUCB-MSCs treatment is not mediated through TIMPs upregulation.
BACKGROUND/AIMS: Stem cell treatment is one of the potential treatment options for ischemic stroke. We recently demonstrated a protective effect of human umbilical cord blood-derived mesenchymal stem cells (HUCB-MSCs) in a rat model of ischemic stroke. The treatment attenuated apoptosis and prevented DNA damage. A collection of published studies, including several from our laboratory, indicated the induction and detrimental role for several matrix metalloproteinases (MMPs) in post-stroke brain injury. We hypothesized that the HUCB-MSCs treatment after focal cerebral ischemia prevents the dysregulation of MMPs and induces the expression of endogenous tissue inhibitors of metalloproteinases (TIMPs) to neutralize the elevated activity of MMPs. METHODS: To test our hypothesis, we administered HUCB-MSCs (0.25 million cells/animal and 1 million cells/animal) intravenously via tail vein to male Sprague-Dawley rats that were subjected to a transient (two-hour) right middle cerebral artery occlusion (MCAO) and one-day reperfusion. Ischemic brain tissues obtained from various groups of rats seven days after reperfusion were subjected to real-time PCR, immunoblot, and immunofluorescence analysis. RESULTS: HUCB-MSCs treatment prevented the induction of MMPs, which were upregulated in ischemia-induced rats that received no treatment. HUCB-MSCs treatment also prevented the induction of TIMPs expression. The extent of prevention of MMPs and TIMPs induction by HUCB-MSCs treatment is similar at both the doses tested. CONCLUSION: Prevention of stroke-induced MMPs upregulation after HUCB-MSCs treatment is not mediated through TIMPs upregulation.
Authors: Koteswara Rao Nalamolu; Ishwarya Venkatesh; Adithya Mohandass; Jeffrey D Klopfenstein; David M Pinson; David Z Wang; Adinarayana Kunamneni; Krishna Kumar Veeravalli Journal: Neuromolecular Med Date: 2019-05-10 Impact factor: 3.843
Authors: Koteswara Rao Nalamolu; Siva Reddy Challa; Casimir A Fornal; Natalia A Grudzien; Laura C Jorgenson; Mouneeb M Choudry; Nathan J Smith; Cassandra J Palmer; David M Pinson; Jeffrey D Klopfenstein; Krishna Kumar Veeravalli Journal: Transl Stroke Res Date: 2021-01-11 Impact factor: 6.800
Authors: Siva Reddy Challa; Koteswara Rao Nalamolu; Casimir A Fornal; Billy C Wang; Ryan C Martin; Elsa A Olson; Ammar L Ujjainwala; David M Pinson; Jeffrey D Klopfenstein; Krishna Kumar Veeravalli Journal: Front Neurosci Date: 2022-10-04 Impact factor: 5.152
Authors: Koteswara Rao Nalamolu; Bharath Chelluboina; Ian B Magruder; Diane N Fru; Adithya Mohandass; Ishwarya Venkatesh; Jeffrey D Klopfenstein; David M Pinson; Krishna M Boini; Krishna Kumar Veeravalli Journal: Stroke Vasc Neurol Date: 2018-03-09
Authors: Koteswara Rao Nalamolu; Bharath Chelluboina; Casimir A Fornal; Siva Reddy Challa; David M Pinson; David Z Wang; Jeffrey D Klopfenstein; Krishna Kumar Veeravalli Journal: Stroke Vasc Neurol Date: 2021-03-19